Pharmaceutical research company
The study will incorporate a one month dose escalation phase followed by 6 months' treatment in an open label study of patients with intermediate or high risk myelofibrosis, including primary myelofibrosis, post polycythemia vera myelofibrosis and post essential thrombocythemia myelofibrosis patients. The study is planned to commence in Q4 2020 and expected to conclude in 2022.
Chief Executive Officer of
PXS 5505 works by inhibiting all of the lysyl oxidase family members that are involved in the bone marrow fibrosis that characterises myelofibrosis. It is hoped that this will have beneficial effects on blood cell production and consequently other aspects of this fatal disease which has a very high unmet medical need.
Contact:
Tel: +61 418 677 701
Email: felicity.moffatt@pharmaxis.com.au
About
Leveraging its small molecule expertise and proprietary amine oxidase chemistry platform,
The company's successor amine oxidase program has developed an oral anti fibrotic LOXL2 inhibitor, aimed at NASH, pulmonary fibrosis (IPF) and other high value fibrotic heart and kidney diseases, with a commercial partnering process underway, a systemic pan LOX inhibitor for acute fibrosis and cancer that will enter a phase 2 study in 2020 and a topical pan LOX inhibitor for scarring that is expected to commence phase 1 studies in 2H 2020.
Forward Looking Statements
Forward looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward looking statements. These forward looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in partnering our LOXL2 program or any of the other products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward looking statements as a result of new information, future events or otherwise.
(C) 2020 Electronic News Publishing, source